Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | Is TP53-mutated high-risk MDS the same disease as TP53-mutated AML?

Peter Valk • 29 Sep 2022
SOHO 2022
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes

Peter Valk, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, shares some insights into a study which aimed to investigate the clinical and molecular differences between TP53-mutated high-risk (HR) myelodysplastic syndromes (MDS) and TP53-mutated acute myeloid leukemia (AML). Dr Valk explains that there were no differences observed between the two diseases, and that patients with both diseases have poor outcomes. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Peter Valk

1:03
Future considerations for MRD in AML
Peter Valk • 29 Sep 2022
2:20
Distinguishing between de novo AML and secondary AML using mutational signatures
Peter Valk • 29 Sep 2022
1:49
The prognostic value of FLT3-ITD residual disease in AML
Peter Valk • 29 Sep 2022
2:44
Ongoing and future AML research at the Valk Lab
Peter Valk • 1 Apr 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals